Business
Mesoblast sees lasting need for COVID treatment beyond a vaccine – Sydney Morning Herald
The next two months will be hugely important for the stem cell therapy company’s research projects, and its growth prospects as it works on a product to treat the deadly disease.
Mesoblast is hoping its flagship product remestemcel-L will be shown to relieve acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company is running a phase 3 trial of the product in US hospitals, but the research is still in its early stages, with a pilot study of the project looking at only 12 patients.
The US Data Safety Monitoring board, which reviews clinical data, had selected a date in early September to complete an initial review of Mesoblast’s phase 3 trial, the comp…
-
Noosa News23 hours agoEnsure voices are heard – Proctor
-
Noosa News18 hours agoMajor crash on Gateway Motorway snarls morning commute
-
General22 hours agoMarine biologist hopes to figure out why sunfish strand along Australia’s southern coast
-
Business24 hours agoASX ETFs to target amidst an ageing population